Gupta Aditya K, Chow Melody
Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center, Sunnybrook site and the University of Toronto, Toronto, Canada.
J Cutan Med Surg. 2004 Jul-Aug;8(4):244-7. doi: 10.1007/s10227-004-0120-x.
Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use.
This article reviews the topical steroid prednicarbate through its mechanism of action, clinical efficacy, and adverse events profile.
Published literature containing the word "prednicarbate" was examined and summarized.
Prednicarbate is a nonhalogenated, double-ester derivative of prednisolone that has been used in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic dermatitis. It has a favorable benefit-risk ratio, low skin atrophy potential, and high anti-inflammatory action.
These characteristics make prednicarbate an ideal alternative agent for children, elderly patients, and those who require long-term intermittent treatment.
外用糖皮质激素一直是治疗各种皮肤疾病的常用选择;然而,其引发显著局部和全身不良事件的可能性,如皮肤萎缩和下丘脑-垂体-肾上腺(HPA)轴抑制,限制了它们的使用。
本文通过其作用机制、临床疗效和不良事件概况对外用糖皮质激素泼尼卡酯进行综述。
对包含“泼尼卡酯”一词的已发表文献进行检查和总结。
泼尼卡酯是泼尼松龙的一种非卤化双酯衍生物,已用于治疗皮质类固醇反应性皮肤病(如特应性皮炎)的炎症和瘙痒表现。它具有良好的效益风险比、低皮肤萎缩可能性和高抗炎作用。
这些特性使泼尼卡酯成为儿童、老年患者以及那些需要长期间歇性治疗的患者的理想替代药物。